Need to keep on prime of the science and politics driving biotech right this moment? Enroll to get our biotech e-newsletter in your inbox.
Hello! It’s Meghana. Right this moment, some wonderful intel on Merck’s Ebola vaccine: Seems, it could actually cut back threat of loss of life, even after an individual has been contaminated. Additionally, buyers guess on one other weight problems drug — this time from BioAge, which is combining Zepbound with a tablet that retains muscle losing at bay.
The necessity-to-know this morning
Biogen reported earnings for the fourth quarter and 2023.
Regulators in Europe accredited Casgevy, a CRISPR-based gene-editing remedy, for individuals with sickle cell illness and beta thalassemia. Casgevy is made by Vertex Prescription drugs and CRISPR Therapeutics.
The FDA prolonged a evaluation of Rocket Prescription drugs’ gene remedy, referred to as Kresladi, by three months to June 30, to permit further time for the evaluation of producing data. Kresladi is being developed to deal with leukocyte adhesion deficiency-I, a uncommon, genetic illness that causes immune deficiency in youngsters.
Roivant and Incyte additionally reported earnings.
AI drug discovery agency Exscientia fired CEO Andrew Hopkins for trigger following an investigation that discovered he had “inappropriate” relationships with two firm staff. David Nicholson, chairman of Exscientia’s board, additionally resigned as a result of he had prior data of Hopkins’ relationships however didn’t notify the corporate.
BioAge’s $170 million Collection D for GLP-1 combo tablet
BioAge, a California biotech growing a mix remedy with the blockbuster weight problems drug Zepbound, simply raised a $170 million Collection D spherical. Its lead candidate, azelaprag, is supposed to assist optimize weight reduction from GLP-1 medicine in order that muscle mass is preserved. BioAge is growing medicine for neuroinflammation as properly.
This funding spherical consists of Sofinnova Investments, Eli Lilly and Amgen’s enterprise arms, and former investor Andreessen Horowitz. Though BioAge has a number of applications, it was the azelaprag-Zepbound mixture that sparked investor curiosity.
Azelaprag mimics the hormone apelin, which is secreted in response to train. It performs a job in regulating metabolism and muscle biology. Apelin ranges dwindle with age — so BioAge, whose medicine purpose to maintain the consequences of getting older at bay — is .
Learn extra.
KalVista’s swelling drug performs properly in section 3
KalVista Prescription drugs’ remedy for the acute swelling episodes seen in hereditary angioedema carried out properly in Section 3 research — which means that the corporate will submit a advertising and marketing utility for the drug, referred to as sebetralstat, by the center of the 12 months. Signs started to abate between 1.6 and 1.8 hours after sufferers took the oral tablet, in comparison with 6.7 hours with placebo. There have been no critical unwanted effects from the drugs.
Proper now, the most typical option to deal with a swelling episode from hereditary angioedema is a generic drugs referred to as icatibant, which is injected subcutaneously. It takes about two hours for symptom aid to start.
Though the market is small, gross sales for sebetralstat may hit $600 million within the U.S. and Europe, Leerink analysts say. Notably, Intellia Therapeutics is growing a CRISPR-based remedy for hereditary angioedema that has the potential to be healing.
Learn extra.
Ebola vaccine works even in individuals who had already been contaminated
A brand new research exhibits that individuals vaccinated in opposition to Ebola with a single dose of Merck’s Ervebo are far much less more likely to die than those that aren’t vaccinated, even when they do develop the illness.
The analysis, printed in Lancet Infectious Ailments, relies on information from the 2018-2020 Ebola Zaire outbreak within the Democratic Republic of the Congo. It confirmed that the inoculation halved the chance of dying amongst individuals who had obtained the vaccine earlier than growing signs — together with those that solely obtained the vaccine only a day or two earlier than getting sick. About 27% of people that had been vaccinated inside two days of turning into symptomatic died, in comparison with 56% in those that have been unvaccinated.
“That’s an enormous discovering,” the research’s first creator advised STAT. “We all know now that vaccination is healthier late than by no means. So that is another reason to make use of the Ebola vaccine.”
Learn extra.
Gilead buying CymaBay for $4.3 billion
Gilead Sciences will purchase CymaBay Therapeutics for $4.3 billion, primarily based totally on the latter’s lead candidate, seladelpar, which goals to deal with a uncommon autoimmune liver illness referred to as major biliary cholangitis. The FDA is reviewing a advertising and marketing utility for seladelpar, with an approval anticipated by Aug. 14.
This acquisition boosts Gilead’s liver illness portfolio, which incorporates its remedies for hepatitis C. It additionally represents a redemption for CymaBay, which skilled some critical setbacks in 2019 when seladelpar did not deal with MASH, previously often known as NASH. In 2022, CymaBay’s inventory was about $2 a share. The cope with Gilead locations shares for CymaBay at $32.50 — 27% increased than they have been simply final week.
Learn extra.
Extra reads
Proteins might predict who will get dementia 10 years later, research finds, Reuters
In wake of Reata buyout, Biogen’s key launch Skyclarys passes muster in EU, FierceBiotech
CSL’s ‘most formidable’ section 3 trial ends in failure for coronary heart assault drug, FierceBiotech
Pssst. If you happen to’ve made it to the top of this text, you could be inquisitive about becoming a member of this secret checklist for an upcoming biotech e-newsletter. Just a few meals for thought.